Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink

John A. Hangasky¹, Thomas A. Waldmann²* and Daniel V. Santi¹*

¹ ProLynx, San Francisco, CA, United States, ² Lymphoid Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, United States

Interleukin-15 (IL-15) is crucial for the proliferation and survival of NK and CD8⁺ T memory cells, and of significant interest in immuno-oncology. Immune cell expansion requires continuous IL-15 exposure above a threshold concentration for an extended period. However, the short t¹/₂ of IL-15 makes this impossible to achieve after a single injection without a high Cmax and toxicities. The most effective way to deliver IL-15 is continuous intra-venous infusion, but this administration mode is impractical. Efforts have been devoted to developing IL-15 agonists which after a single injection maintain the cytokine in a narrow therapeutic window for a long period. Enigmatically, although the half-life extension technologies used often extend the half-life of a protein to 1 or more weeks, the modified IL-15 agonists studied usually have systemic elimination half-lives of only a few hours and rarely much longer than 1 day. These short half-lives—common to all circulating IL-15 agonists thus far reported—can be explained by a dynamic increase in clearance of the agonists that accompanies target immune cell proliferation. What is needed is an IL-15 agonist that is as effective as continuous intravenous infusion, but with the convenience and acceptance of single injections at 1-week or longer intervals.

Keywords: cytokine, immuno-oncology, NK cells, CD8⁺ T cells, target-mediated drug disposition, interleukin-15, pharmacokinetics

INTRODUCTION

Interleukin 15 (IL-15) is a ~14 kDa four-α-helix protein belonging to a family of six interleukins that use a common cytokine-receptor γ-chain (1). The cytokine is crucial in the proliferation, maintenance, and survival of NK and CD8⁺ T memory cells, and is of major interest in immuno-oncology (2). IL-15 stimulates immune cell responses through the same dimeric IL-2/15Rβγ receptor complex as IL-2 (Figure 1A), but the two cytokines exhibit functionally distinct activities due to their private α-receptor subunits. As a consequence, either IL-15 or IL-2 stimulates NK and CD8⁺ T cells, but only IL-2 binds to and stimulates regulatory T cells that possess the IL-2Rα in a trimeric Rαβγ complex. IL-15 is expressed in association with its high affinity IL-15Rα on the surface of IL-15-producing cells and is trans-presented to immune cells that express dimeric IL-2/15Rβγ subunits (3). Once bound to target NK and memory CD8⁺ T cells, IL-15 stimulates their proliferation, and supports their survival (4, 5). Despite dramatic augmentation of NK cells and CD8⁺ T cells, IL-15 has minimal anticancer activity as a single agent. However, in combination with other immuno-oncology agents, it shows significant efficacy and it is in this setting that IL-15 will likely find success (6).
The pharmacokinetics and pharmacodynamics of IL-15 agonists are profoundly impacted by target-mediated drug disposition (TMDD) wherein the cytokine is consumed and cleared by target immune cells (12–14)—a “cytokine sink.” At high initial IL-15 concentrations, target cells are saturated with cytokine—(i.e., capacity-limited TMDD)—and clearance of the agonist is dominated by renal and/or metabolic elimination. IL-15 subsequently causes a time-dependent proliferation of target immune cells and commensurate time-dependent increase of cytokine consumption and clearance; once expanding target cells exceed the cytokine concentration and \( K_d \) of the IL-15–R\( \beta \gamma \) the pharmacokinetics manifest as TMDD. The purposes of this review are to consolidate and scrutinize dispersed reports of the pharmacokinetics of IL-15 agonists, and to evaluate the evidence for generation of a dynamic cytokine sink that expands concomitantly with the proliferation of IL-15 target immune cells.

Target Immune Cell Proliferation and Maintenance

NK and memory T cell proliferation requires continuous IL-15 exposure at a level above a threshold concentration for an extended period (4, 5). However, with a \( t_{1/2} \) of only \( \sim 2.5 \) h in the human it is impossible to achieve long exposure of IL-15 after a single IV injection without a very high \( C_{\text{max}} \) and resultant toxicities (15). For example, a bolus IV dose of 3 \( \mu \)g/kg IL-15 is necessary to maintain serum IL-15 at \( \geq 1 \) pM—\( \sim 10 \)-fold lower than the \( K_d \) of IL-15 for IL-2/15R\( \beta \gamma \) for a 24 h period but gives a \( C_{\text{max}} \) of \( \sim 3,000 \) pM, some 30-fold higher than the 100 pM \( C_{\text{max}} \) with a 0.3 \( \mu \)g/kg MTD (15). A possible and popular solution to this problem is to simply extend the \( t_{1/2} \) of the cytokine. This would concurrently flatten the \( C \) vs. \( t \) plot, enable prolonged exposure to optimize efficacy, and reduce the \( C_{\text{max}} \) peak responsible for toxicities.

Continuous IV (CIV) infusions of therapeutics are often safer than bolus injections since the flat \( C \) vs. \( t \) profile is absent the high \( C_{\text{max}} \) peak often associated with toxicity. Indeed, CIV infusion is the most efficient delivery method for IL-15, requiring low doses and resulting in large increases of target immune cells (16). In humans, 2 \( \mu \)g IL-15/kg/day of CIV infusion for 10 days led to a 5-fold increase in circulating CD8\(^+\) T cells, a 38-fold increase in the total NK cells, and a massive 358-fold increase in CD56\(^{bright}\) NK cells. Usually, infusing a drug at a constant rate that is balanced with its rate of elimination results in maintenance of a constant serum level. However, with CIV infusion of IL-15 serum levels decreased over the time of infusion—starting at \( \sim 360 \) pM and lowering to \( \sim 70 \) pM by the end of the infusion period—indicating a time dependent increase in IL-15 clearance. This is in accord with an expanding cytokine sink where the initial lower clearance rate reflects capacity-limited TMDD (12, 14) but which after target expansion to about \( 10^{-9} \) M presents a large receptacle exceeding both IL-15 concentration and the \( K_d \) of the IL-15–R\( \beta \gamma \) complex; under saturating sink conditions, the clearance of IL-15 would be maximal. An interesting transition of the IL-15 dose-exposure relationship occurs between infusion of 0.5- and 1 \( \mu \)g/kg/day whereby a doubling in dose results in a >45-fold increase in serum IL-15. This further supports a conversion from capacity-limited TMDD to a clearance mechanism whereby the IL-15 exceeds the capacity of the cytokine sink. Notwithstanding, CIV infusion of IL-15 for 10 days is an inconvenient, expensive mode of long-term drug administration and is unacceptable to both patients and physicians. It would be desirable to have an IL-15 agonist that could be administered as single injections at intervals of 1 or more weeks.

Pharmacokinetics of IL-15 Agonists

There have been extensive efforts to develop potent, long-acting IL-15 receptor agonists—referred to as “super-agonists” (17)—which after a single injection maintains the agonist in a narrow therapeutic window for a long period. Figure 1B depicts IL-15 agonists in clinical trials that have reported pharmacokinetic data, and Table 1 presents their reported \( t_{1/2} \) values in different species with different routes of administration. The approaches used to increase the \( t_{1/2} \) of IL-15 generally involve increasing

---

**FIGURE 1** IL-15 receptor, receptor agonists, half-lives, and immune cell proliferation. (A) IL-15 and IL-2 receptor specificities. IL-15 is trans-presented in association with IL-15R\( \alpha \) to R\( \beta \gamma \) subunits also used by IL-2. Trans-presentation of IL-15/IL-15R\( \alpha \) to responding cells leads to the activation of JAK1/3 which phosphorylate STAT3/5 to prompt transcription of IL-15-modulated genes. IL-2 binds to cells with the same R\( \beta \gamma \) subunits, as well as the high-affinity trimeric IL-2 R\( \alpha \beta \gamma \) receptor on T\( \text{reg} \) cells. (B) IL-15R agonists in human clinical trials. i) NKTR-255 is a PEGylated IL-15 (7), ii) RLI is a fusion of the C-terminus of the IL-15R\( \alpha \) domain to the N-terminus of IL-15 via a 20 AA linker (6), iii) HetIL-15 (aka NIZ985) is a heterodimeric complex of IL-15 and the extracellular R\( \beta \gamma \), and (iv) ALT-803 (aka N-803) has IL-15N72D bound to a Fc –IL-15R\( \alpha \) Sushi domain fusion (10, 11). (C) Receptor-mediated cell proliferation and increased cytokine consumption. The cytokine binds its extracellular receptor, signals to cause cell proliferation, and is endocytosed with variable degrees of destruction. With proliferating cells consuming more of the cytokine, clearance increases as target immune cells expand.
the molecular size to reduce renal elimination; they include incorporation of part of the IL-15Rα and/or attachment to PEG or Fc to the cytokine. There are also current investigations— not covered here—of IL-2Rβ “biased” IL-2 constructs that bind poorly to IL-2Rα in the trimeric receptor of regulatory T cells, and specifically bind to IL-2R15Rβ mimicking the specificity of IL-15 (27, 28) which are reviewed in Klein et al. (29).

Significantly, and enigmatically, although the half-life extension technologies used often lengthen the t1/2 of a protein to a week or longer in humans, the IL-15 agonists studied have systemic elimination t1/2 of not much longer than 1 day and usually only several hours (Table 1). Indeed, the only current IL-15 agonists that might be sufficient for QWk injections are the SC administered ALT-803 and the IV-administered PEGylated IL-15, NKTR-255. Interestingly, IV administration of the “long-acting” ALT-803 agonist in humans has a dose-dependent elimination t1/2 of ~0.75 to 5 h (26), which is not significantly different than the 2.5 h t1/2 of IV-administered native IL-15 (15). The dose-dependent elimination rate is likely due to a significant proportion of the drug being consumed by target cells—i.e., TMDD—as observed with NKTR-255 (13)]. Thus, the longer apparent t1/2 of 30 h for SC administered ALT-803 is not due to the retardation of systemic elimination intended by its large size, but rather due to slow absorption from the injection site. Regardless, even with the 30 h t1/2 for SC ALT-803 in humans, the level of exposure needed for proliferation and survival of target cells is sustainable for only a few days, and >90% of the drug will be eliminated in 4 days.

Although slow SC absorption provides a simple, practical approach toward achieving half-life extension, it may have unintended shortcomings. For example, SC administration of proteins may or may not have adequate bioavailability. For native IL-15, the SC t1/2 in humans is close to that of the IV injection (~4 h for SC vs. 2.5 h for IV), and the bioavailability is estimated from reported data to be near 100% (15, 22). Hence, most of the SC-administered IL-15 is rapidly and completely transferred to the systemic circulation. In contrast, in humans SC ALT-803 shows a long t1/2 of ~30 h but a bioavailability of only about 3% (26). Interestingly, the 40 pM C_{max} of the agonist administered SC is some 100-fold lower than that of the same amount injected IV, yet it is significantly more effective at NK and CD8^{+} T cell expansion; clearly, the superior pharmacodynamic effects of SC vs IV administered ALT-803 are due to its longer effective t1/2. The very low bioavailability of SC ALT-803 reveals that most (~97%) of the administered drug never reaches the systemic circulation and may activate and be consumed by immune cells near the injection site. Hence, the substantial local toxicity of SC-injected ALT-803—which is not observed with IL-15—may be due to the very high level of the super-agonist deposited at the site of injection and its slow departure. Enigmatically, the problem cannot be solved by simply changing the mode of administration of ALT-803 from SC to IV or intraperitoneal (30) injections since the t1/2 of ALT-803 via these routes are so much lower. Whether the other IL-15 super-agonists—such as hetIL-15 and RLI—will face the same conundrum in humans is not known since relevant pharmacokinetic parameters have not yet been reported.

**IL-15 Consumption by a Cytokine Sink**

Why do the IL-15 agonists have shorter than expected t1/2? There is abundant evidence for an IL-15-induced “cytokine sink” that increases with proliferation of target immune cells (Figure 1C) and causes commensurate increases in the consumption/clearance of IL-15 (Table 1)—a prototypical example of “drug-induced” or “dynamic” TMDD (14). First, CIV infusion of IL-15 in monkeys and in man initially results in the expected steady state level of serum IL-15 which then decreases ~4- to 5-fold over time (16, 21); this unusual effect can best be explained by a time dependent increase of clearance of IL-15. Second, sequential SC administration of the same doses of the super-agonist hetIL-15 results in decreasing C_{max} and C_{min} upon repeated injections (24); but, when the dose is doubled in each injection by a “doubling step dose” a constant C_{max} and C_{min} can be maintained. This shows that increased hetIL-15 dosing is necessary to satiate the increased appetite for consumption by expanded target cells. Third, pharmacokinetic modeling of cergutuzumab amunaleukin—a CEA targeted immunocytokine containing an IL-15-like IL-2Rβ biased IL-2 mutein—revealed expansion of a drug-induced peripheral sink that increases clearance (27). Fourth, the IL-15/ILRα Fc-fusion XmAb24306 shows low potency but a long t1/2, which is in accord with the inverse relationship between cytokine-induced expansion of a peripheral sink and cytokine t1/2 (31). Finally, several IL-15

### Table 1

| Agonist | Route | t1/2, hr |
|---------|-------|---------|
| IL-15   | IV    | 0.64    |
|         | SC    | 0.67    |
|         | IP    | 0.50    |
| RLI     | IP    | 3m     |
| hetIL-15| IV    | 1.5     |
|         | SC    | 12      |
|         | IP    | 4       |
| ALT-803 | IV    | 7.5     |
|         | SC    | 7.5     |
| NKTR-255| IV    | 14      |

*aOmissions indicate data is not available.

**References**

1. Han et al. (18).
2. Waldmann et al. (19).
3. Conlon et al. (15).
4. Zhao et al. (20).
5. Snieker et al. (21).
6. Miller et al. (23).
7. Bessard et al. (23).
8. Chertova et al. (9).
9. Bergamaschi et al. (24).
10. Liu et al. (11).
11. Rhode et al. (10).
12. Margolin et al. (25).
13. Romee et al. (23).
14. Kuo (7).
fusions show unexpectedly high rates of systemic elimination that are best explained by a large peripheral sink. The ~114 kDa ALT-803—expected to have a slow systemic elimination rate because of its large size—has an average elimination t1/2 of ~3 h in humans when injected IV; and, connection of RLI to the carboxy terminus of anti-CD20 rituximab—which has a t1/2 of about 100 h in mice—results in a large fusion protein with >10-fold lower t1/2 than the antibody carrier itself (32). Hence, expansion of target cells by IL-15 agonists is accompanied by a dynamic increased consumption, increased clearance, and decreased lifetime of the agonists.

Summary

The efficacy of IL-15 agonists in stimulating target immune cell proliferation is paradoxically coupled to its more rapid consumption and clearance. By far, the most efficacious way to deliver IL-15 is by CIV infusion, but this mode of administration is generally impractical. The available IL-15 super-agonists are administered as single injections at intervals of several days to 1 week and are more practical to administer than CIV infusion; however, because of the expanding consumptive sink that accompanies target cell proliferation, they have relatively short systemic half-lives and do not achieve the level of immune cell proliferation and maintenance as CIV infusion. Ideally, what is needed is an IL-15 agonist that is as effective as CIV infusion, but with the convenience and acceptance of single injections at one-week or longer intervals. In a forthcoming report, we will describe our efforts at developing a very slow-releasing hydrogel depot of IL-15 that attempts to achieve this goal.

AUTHOR CONTRIBUTIONS

JH wrote and edited the manuscript. DS conceived, wrote, and edited the manuscript. TW provided critical comments, concepts, and insights. All authors read and agreed to the content of this work prior to submission. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. (2006) 6:595–601. doi: 10.1038/nri1901
2. Robinson TO, Schluns KS. The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett. (2017) 190:159–68. doi: 10.1016/j.imlet.2017.08.010
3. Giron-Michel J, Giuliani M, Fogli M, Brouty-Boye D, Ferrini S, Baychelier F, et al. Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood (2005) 106:2302–10. doi: 10.1182/blood-2005-01-0064
4. Judge AD, Zhang X, Fujii H, Surch CD, Sprent J. Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med. (2002) 196:935–46. doi: 10.1084/jem.20020772
5. Berard M, Brandt K, Bulfone-Paus S, Tough DF. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol. (2003) 170:5018–26. doi: 10.4049/jimmunol.170.10.5018
6. Waldmann TA, Dubois S, Milojkovic MD, Conlon KC, IL-15 in the combination immunotherapy of cancer. Front Immunol. (2020) 11:868. doi: 10.3389/fimmu.2020.00868
7. Kuo P. NKTR-255: Accessing IL-15 Therapeutic Potential through Robust andSustained Engagement of Innate and Adaptive Immunity. In: CHI 2nd Annual Emerging Immuno-Oncology Targets Conference. Boston, MA. (2018).
8. Mortier E, Quemener A, Vissio P, Lorenzen I, Boublik Y, Grotzinger J, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. J Biol Chem. (2002) 278:16121–9. doi: 10.1074/jbc.M203082200
9. Chertova E, Bergamaschi C, Chertov O, Sowder R, Bear J, Roser JD, et al. Characterization and favorable in vivo properties of heterodimeric soluble IL-15/IL-15Ra cytokine compared to IL-15 monomer. J Biol Chem. (2013) 288:18093–103. doi: 10.1074/jbc.M113.461756
10. Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, et al. Comparison of the superagonist complex, ALT-803, to IL15 by continuous intravenous infusion to adult patients with solid tumors in a Phase I trial Induced dramatic NK-cell subset expansion. Clin Cancer Res. (2019) 25:4945–54. doi: 10.1158/1078-0432.CCR-18-3468
11. Han KP, Zhu X, Liu B, Jeng E, Kong L, Yovandich JL, et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. (2011) 56:804–10. doi: 10.1016/j.cyto.2011.09.028
12. Waldmann TA, Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, et al. IL15 by continuous intravenous infusion to adult patients with solid tumors in a Phase I trial Induced dramatic NK-cell subset expansion. Clin Cancer Res. (2019) 25:4945–54. doi: 10.1158/1078-0432.CCR-18-3468
13. Bhasi K, Obalapur P, Kuo P, Zhang R, Sims P, Miyazaki T, et al. NKTR-255 "Exhibits target mediated drug disposition and stimulates proliferation of cytotoxic immune cells in cynomolgus monkeys," in American Conference on Pharmacometrics, Poster #T-039 (San Diego, CA). (2018).
14. Hua F, Flowers D, Kiroucac DC, Appar JF. Abstract 678: drug-induced TMDD: a novel class of PK models relevant to Immune-stimulating therapies. Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR. Cancer Res. (2019). 79(13Suppl):e678. doi: 10.1158/1538-7445.AM2019-678
15. Conlon KC, Rugli E, Welske HC, Rosenberg SA, Fojo AT, Morris JC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8+ T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. (2015) 33:74–82. doi: 10.1200/JCO.2014.57.3329
16. Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, et al. IL15 by continuous intravenous infusion to adult patients with solid tumors in a Phase I trial Induced dramatic NK-cell subset expansion. Clin Cancer Res. (2019) 25:4945–54. doi: 10.1158/1078-0432.CCR-18-3468
17. Knuudson KM, Hodge JW, Schlom J, Gameiro SR. Rationale for IL-15 superagonists in cancer immunotherapy. Expert Opin Biol Ther. (2020) 20:1–5. doi: 10.1080/14712598.2020.1738379
18. Han KP, Zhu X, Liu B, Jeng E, Kong L, Yovandich JL, et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. (2011) 56:804–10. doi: 10.1016/j.cyto.2011.09.028
19. Waldmann TA, Conlon KC, Roederer M, Perera LP, Smedley JV, Macallister RP, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. (2011) 117:4787–95. doi: 10.1182/blood-2010-10-114156
20. Zhao M, Luo M, Xie Y, Jiang H, Caglieri C, Li N, et al. Development of a recombinant human IL-15:IL-15Ra/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model. Biomed Pharmacother. (2019) 112:108677. doi: 10.1016/j.biopha.2019.108677
human IL15 (rhlIL15) in adults with advanced solid tumors. Clin Cancer Res. (2018) 24:1525–35. doi: 10.1158/1078-0432.CCR-17-2451

23. Bessard A, Sole V, Bouchaud G, Quemener A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther. (2009) 8:2736–45. doi: 10.1158/1535-7163.MCT-09-0275

24. Bergamaschi C, Watson DC, Valentin A, Bear J, Peer CJ, Figg WD, et al. Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques. Cytokine. (2018) 108:213–24. doi: 10.1016/j.cyto.2018.01.011

25. Margolin K, Morishima C, Velchetti V, Miller JS, Lee SM, Silk AW, et al. Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors. Clin Cancer Res. (2018) 24:5552–61. doi: 10.1158/1078-0432.CCR-18-0945

26. Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. (2018) 131:2515–27. doi: 10.1182/blood-2017-12-823757

27. Ribba B, Boetsch C, Nayak T, Grimm HP, Charo J, Evers S, et al. Prediction of the optimal dosing regimen using a mathematical model of tumor uptake for immunocytokine-based cancer immunotherapy. Clin Cancer Res. (2018) 24:3325–33. doi: 10.1158/1078-0432.CCR-17-2953

28. Boyman O, Arenas-Ramirez N. Development of a novel class of interleukin-2 immunotherapies for metastatic cancer. Swiss Med Wkly. (2019) 149:w14697. doi: 10.4414/smw.2019.14697

29. Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundshofer A, Nayak T, Vugts DJ, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. (2017) 6:e1277306. doi: 10.1080/2162402X.2016.1277306

30. Felices M, Chu S, Kodak B, Bendick L, Ryan C, Lenvik AI, et al. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol Oncol. (2017) 145:453–61. doi: 10.1016/j.ygyno.2017.02.028

31. Bernet MJ, Varma R, Bonzon C, Rashid R, Bogaert L, Liu K, et al. Abstract 5565: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure. Cancer Res. (2018) 78 (13 Suppl.):5565. doi: 10.1158/1538-7445.AM2018-5565

32. Vincent M, Teppaz G, Lajoie L, Sole V, Bessard A, Maillasson M, et al. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. Mabs. (2014) 6:1026–37. doi: 10.4161/mabs.28699

Conflict of Interest: JH and DS are employees and shareholders of ProLynx.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Hangasky, Waldmann and Santi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.